BioArctic
Sweden - StockholmBiotechnology
Focus: BioArctic is a Swedish public biotech company focused on CNS treatments, particularly in neurology with early-stage clinical programs in spinal cord injury and Parkinson's disease.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at BioArctic?
AI assessmentBioArctic is a high-risk, early-stage CNS-focused biotech suited only for researchers/scientists willing to bet on two Phase 1/2 programs with no near-term approval catalyst.
Why Work Here
- Early-stage pipeline with potential for significant career growth if Phase 2 programs advance—exidavnemab in Parkinson's represents a competitive neurology bet
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SC0806 and rehabilitation
Spinal Cord InjuryClinical Trials (1)
NCT02490501Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects
Phase 1/2Help build intelligence for BioArctic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.